Literature DB >> 20924677

Generic and therapeutic substitutions: are they always ethical in their own terms?

Mubarak AlAmeri1, Miran Epstein, Atholl Johnston.   

Abstract

Cost containment-driven drug substitution, whether generic or therapeutic, is defined as switching to another drug because it is cheaper. So far, such substitutions have drawn their public legitimacy from the general belief that they would not compromise the clinical interests of patients and certainly not violate their right to decline them if they did. This article does not enter the debate on whether or not such substitutions must give exclusive priority to the patient's interests and choices in order to be ethical. Indeed, it acknowledges the plurality of views on this matter. It simply argues that when such substitutions involve a cheaper drug that is known to have different effects and side effects, or even a drug whose effects and side effects are unknown, they are potentially deleterious to the patient, and that no competent and well-informed patient would ever consent to them. Such substitutions are thus unethical in their very own terms.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20924677     DOI: 10.1007/s11096-010-9429-2

Source DB:  PubMed          Journal:  Pharm World Sci        ISSN: 0928-1231


  26 in total

Review 1.  The evidence base for tight blood pressure control in the management of type 2 diabetes mellitus.

Authors:  Vincenza Snow; Kevin B Weiss; Christel Mottur-Pilson
Journal:  Ann Intern Med       Date:  2003-04-01       Impact factor: 25.391

Review 2.  Therapeutic substitution: guilty until proven innocent.

Authors:  Dean J Kereiakes; James T Willerson
Journal:  Circulation       Date:  2003-11-25       Impact factor: 29.690

3.  Does bioequivalence between modified cyclosporine formulations translate into equal outcomes?

Authors:  David J Taber; G Mark Baillie; Elizabeth E Ashcraft; Jeffrey Rogers; Angello Lin; Fuad Afzal; Prabhakar Baliga; P R Rajagopalan; Kenneth D Chavin
Journal:  Transplantation       Date:  2005-12-15       Impact factor: 4.939

4.  Building bridges between academic research and policy formulation: when costing less means costing more.

Authors:  Amiram Gafni; Stephen Birch
Journal:  Pharmacoeconomics       Date:  2007       Impact factor: 4.981

5.  Are generic formulations of carvedilol of inferior pharmaceutical quality compared with the branded formulation?

Authors:  Julian C Smith; Giorgio Tarocco; Fabio Merazzi; Urs Salzmann
Journal:  Curr Med Res Opin       Date:  2006-04       Impact factor: 2.580

6.  Comparative bioavailability of three different preparations of rifampicin.

Authors:  R Pähkla; J Lambert; P Ansko; P Winstanley; P D Davies; R A Kiivet
Journal:  J Clin Pharm Ther       Date:  1999-06       Impact factor: 2.512

7.  What are the obstacles to generic substitution? An assessment of the behaviour of prescribers, patients and pharmacies during the first year of generic substitution in Sweden.

Authors:  Karolina Andersson; Christian Sonesson; Max Petzold; Anders Carlsten; Knut Lönnroth
Journal:  Pharmacoepidemiol Drug Saf       Date:  2005-05       Impact factor: 2.890

8.  Differentiation of innovator versus generic cyclosporine via a drug interaction on sirolimus.

Authors:  John M Kovarik; Adele Noe; Yibin Wang; Irene Mueller; Gilberto DeNucci; Robert L Schmouder
Journal:  Eur J Clin Pharmacol       Date:  2006-03-18       Impact factor: 2.953

9.  Stability and in vitro release profile of enalapril maleate from different commercially available tablets: possible therapeutic implications.

Authors:  Dione Marçal Lima; Leandro Dias dos Santos; Eliana Martins Lima
Journal:  J Pharm Biomed Anal       Date:  2008-03-04       Impact factor: 3.935

10.  Bioequivalence and other unresolved issues in generic drug substitution.

Authors:  Peter Meredith
Journal:  Clin Ther       Date:  2003-11       Impact factor: 3.393

View more
  3 in total

1.  Generic and therapeutic substitution: ethics meets health economics.

Authors:  Steven Simoens
Journal:  Int J Clin Pharm       Date:  2011-03-24

2.  Generic and therapeutic substitution: a response to our critic.

Authors:  Mubarak Nasser Al Ameri; Miran Epstein; Atholl Johnston
Journal:  Int J Clin Pharm       Date:  2011-09-17

3.  The differences between the branded and generic medicines using solid dosage forms: In-vitro dissolution testing.

Authors:  Mubarak Nasser Al Ameri; Nanda Nayuni; K G Anil Kumar; David Perrett; Arthur Tucker; Atholl Johnston
Journal:  Results Pharma Sci       Date:  2011-12-07
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.